These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23314273)

  • 1. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application.
    Ariza ME; Williams MV; Wong HK
    Clin Immunol; 2013 Feb; 146(2):131-9. PubMed ID: 23314273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal antibodies targeting IL-17A or its receptor in psoriasis: a new therapeutic approach?].
    Bonnet MC; Bagot M; Bensussan A
    Med Sci (Paris); 2012 Dec; 28(12):1035-7. PubMed ID: 23290394
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
    Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
    Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model.
    Nakajima K; Kanda T; Takaishi M; Shiga T; Miyoshi K; Nakajima H; Kamijima R; Tarutani M; Benson JM; Elloso MM; Gutshall LL; Naso MF; Iwakura Y; DiGiovanni J; Sano S
    J Immunol; 2011 Apr; 186(7):4481-9. PubMed ID: 21346238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis.
    Nakajima K
    J Dermatol; 2012 Mar; 39(3):219-24. PubMed ID: 22352845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside--translational research in psoriasis.
    Prinz JC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():1-4. PubMed ID: 20831702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
    Levin AA; Gottlieb AB
    J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17 targeted therapies for psoriasis.
    Chiricozzi A; Krueger JG
    Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.
    Zheng Y; Danilenko DM; Valdez P; Kasman I; Eastham-Anderson J; Wu J; Ouyang W
    Nature; 2007 Feb; 445(7128):648-51. PubMed ID: 17187052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and early clinical data on IL-17 blockade in psoriasis.
    Nwe SM; Champlain AH; Gordon KB
    Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.
    Zhu S; Qian Y
    Clin Sci (Lond); 2012 Jun; 122(11):487-511. PubMed ID: 22324470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
    Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
    Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-17 with ixekizumab in patients with psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Immunotherapy; 2015; 7(9):957-66. PubMed ID: 26569072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis.
    Roostaeyan O; Kivelevitch D; Menter A
    Immunotherapy; 2017 Sep; 9(12):963-978. PubMed ID: 28879789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch DN; Menter A
    Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.
    Krueger JG; Fretzin S; Suárez-Fariñas M; Haslett PA; Phipps KM; Cameron GS; McColm J; Katcherian A; Cueto I; White T; Banerjee S; Hoffman RW
    J Allergy Clin Immunol; 2012 Jul; 130(1):145-54.e9. PubMed ID: 22677045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous application of leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: an immunohistological study.
    Hendriks AG; Keijsers RR; Seyger MM; van de Kerkhof PC; van Erp PE
    Skin Pharmacol Physiol; 2014; 27(3):120-6. PubMed ID: 24401330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.